The safety of neoadjuvant hormonal treatment in infants with cryptorchidism.

Fiala V, Jiraskova Z, Drlik M, Sedlacek J, Dite Z, Novakova P, Kocvara R, Kalousova M, Soukup V

Journal of pediatric urology19 May 2022Cited by 2 (Europe PMC)

PMID35691791DOI10.1016/j.jpurol.2022.05.010PepBankPUB-35691791

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In infant boys with unilateral cryptorchidism, penile size increased significantly and similarly in the gonadorelin and control groups.
In plain wordsIn infant boys with an undescended testis, penile size grew similarly with and without gonadorelin.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
No significant changeChange in penile size
Study
n = 36
Comparator
No gonadorelin (control)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · intranasalAs given in this study (human).
Source sentences
Summary
Between minipuberty (mean 3 months) and time of orchidopexy (mean 11 months of age) the penile size increased significantly and similarly in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Those with non-syndromic cryptorchidism and palpable or sonographically detected testis were randomly assigned into two groups: with and without intranasal gonadorelin treatment.
Summary · context
Inclusion criteria were met by 36 boys (21 in GNRH and 15 in the control groups).
Report a problemFND-3569179101
02HumanRandomized controlled trialEfficacy outcome
In infant boys with unilateral cryptorchidism, gonadorelin did not change the volume of the descended testis differently from control.
In plain wordsIn infant boys with an undescended testis, gonadorelin did not change descended testis volume compared with no treatment.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
No significant changeChange in volume of descended testis
Study
n = 36
Comparator
No gonadorelin (control)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · intranasalAs given in this study (human).
Source sentences
Summary
There was no significant difference in the change of the volume of descended testis between the groups
2 context sentences(design, population, supporting numbers)
Summary · context
Those with non-syndromic cryptorchidism and palpable or sonographically detected testis were randomly assigned into two groups: with and without intranasal gonadorelin treatment.
Summary · context
Inclusion criteria were met by 36 boys (21 in GNRH and 15 in the control groups).
Report a problemFND-3569179102
03HumanRandomized controlled trialEfficacy outcome
In infant boys with unilateral cryptorchidism, gonadorelin did not change the volume of the undescended testis differently from control.
In plain wordsIn infant boys with an undescended testis, gonadorelin did not change undescended testis volume compared with no treatment.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
No significant changeChange in volume of undescended testis
Study
n = 36
Comparator
No gonadorelin (control)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · intranasalAs given in this study (human).
Source sentences
Summary
There was no significant difference in the change of the volume of descended testis between the groups nor of the volume of undescended testis.
2 context sentences(design, population, supporting numbers)
Summary · context
Those with non-syndromic cryptorchidism and palpable or sonographically detected testis were randomly assigned into two groups: with and without intranasal gonadorelin treatment.
Summary · context
Inclusion criteria were met by 36 boys (21 in GNRH and 15 in the control groups).
Report a problemFND-3569179103
04HumanRandomized controlled trialEfficacy outcome
In infant boys with unilateral cryptorchidism, gonadorelin did not change the drop in LH differently from control.
In plain wordsIn infant boys with an undescended testis, gonadorelin did not change LH levels compared with no treatment.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
No significant changeChange in LH level
Study
n = 36
Comparator
No gonadorelin (control)
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · intranasalAs given in this study (human).
Source sentences
Summary
we did not find any significant difference in the change (drop) of hormonal levels of LH, FSH, Testosterone, Inhibin B and AMH (Table 1a)
2 context sentences(design, population, supporting numbers)
Summary · context
Those with non-syndromic cryptorchidism and palpable or sonographically detected testis were randomly assigned into two groups: with and without intranasal gonadorelin treatment.
Summary · context
Inclusion criteria were met by 36 boys (21 in GNRH and 15 in the control groups).
Report a problemFND-3569179104
05HumanRandomized controlled trialEfficacy outcome
In infant boys with unilateral cryptorchidism, gonadorelin did not change the drop in FSH differently from control.
In plain wordsIn infant boys with an undescended testis, gonadorelin did not change FSH levels compared with no treatment.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
No significant changeChange in FSH level
Study
n = 36
Comparator
No gonadorelin (control)
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · intranasalAs given in this study (human).
Source sentences
Summary
we did not find any significant difference in the change (drop) of hormonal levels of LH, FSH, Testosterone, Inhibin B and AMH (Table 1a)
2 context sentences(design, population, supporting numbers)
Summary · context
Those with non-syndromic cryptorchidism and palpable or sonographically detected testis were randomly assigned into two groups: with and without intranasal gonadorelin treatment.
Summary · context
Inclusion criteria were met by 36 boys (21 in GNRH and 15 in the control groups).
Report a problemFND-3569179105
06HumanRandomized controlled trialEfficacy outcome
In infant boys with unilateral cryptorchidism, gonadorelin did not change the drop in testosterone differently from control.
In plain wordsIn infant boys with an undescended testis, gonadorelin did not change testosterone levels compared with no treatment.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
No significant changeChange in testosterone level
Study
n = 36
Comparator
No gonadorelin (control)
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · intranasalAs given in this study (human).
Source sentences
Summary
we did not find any significant difference in the change (drop) of hormonal levels of LH, FSH, Testosterone, Inhibin B and AMH (Table 1a)
2 context sentences(design, population, supporting numbers)
Summary · context
Those with non-syndromic cryptorchidism and palpable or sonographically detected testis were randomly assigned into two groups: with and without intranasal gonadorelin treatment.
Summary · context
Inclusion criteria were met by 36 boys (21 in GNRH and 15 in the control groups).
Report a problemFND-3569179106
07HumanRandomized controlled trialEfficacy outcome
In infant boys with unilateral cryptorchidism, gonadorelin did not change the drop in inhibin B differently from control.
In plain wordsIn infant boys with an undescended testis, gonadorelin did not change inhibin B levels compared with no treatment.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
No significant changeChange in inhibin B level
Study
n = 36
Comparator
No gonadorelin (control)
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · intranasalAs given in this study (human).
Source sentences
Summary
we did not find any significant difference in the change (drop) of hormonal levels of LH, FSH, Testosterone, Inhibin B and AMH (Table 1a)
2 context sentences(design, population, supporting numbers)
Summary · context
Those with non-syndromic cryptorchidism and palpable or sonographically detected testis were randomly assigned into two groups: with and without intranasal gonadorelin treatment.
Summary · context
Inclusion criteria were met by 36 boys (21 in GNRH and 15 in the control groups).
Report a problemFND-3569179107
08HumanRandomized controlled trialEfficacy outcome
In infant boys with unilateral cryptorchidism, gonadorelin did not change the drop in AMH differently from control.
In plain wordsIn infant boys with an undescended testis, gonadorelin did not change AMH levels compared with no treatment.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
No significant changeChange in AMH level
Study
n = 36
Comparator
No gonadorelin (control)
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · intranasalAs given in this study (human).
Source sentences
Summary
we did not find any significant difference in the change (drop) of hormonal levels of LH, FSH, Testosterone, Inhibin B and AMH (Table 1a)
2 context sentences(design, population, supporting numbers)
Summary · context
Those with non-syndromic cryptorchidism and palpable or sonographically detected testis were randomly assigned into two groups: with and without intranasal gonadorelin treatment.
Summary · context
Inclusion criteria were met by 36 boys (21 in GNRH and 15 in the control groups).
Report a problemFND-3569179108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.